NascaCell Technologies AG
NascaCell Technologies AG and the University of Massachusetts develop Aptamers and Microbodies™ against Botulinum toxin (Botox)
NascaCell Technologies AG / Alliance Release of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer / publisher is solely responsible for the content of this announcement. ---------------------------------------------------------------------- Munich, October 18, 2007 – NascaCell Technologies AG and the University of Massachusetts Dartmouth (UMass Dartmouth) signed a cooperation agreement to develop specific inhibitors of the bacterial Botulinum toxin (Botox). The group of Dr. Shuowei Cai and Prof. Dr. Bal Ram Singh contributes with their excellent expertise in the area of Botulinum toxin research and NascaCell applies its Microbody™ and Aptamer technologies. As part of the collaboration, NascaCell will select specific aptamers against a sub-unit of the target protein as a service project for the University of Massachusetts Dartmouth to study the molecular mode of action of this toxin. In addition, UMass Dartmouth will provide their expertise and know-how to support NascaCell in the development of proprietary Microbodies™ as inhibitors and pharmaceutical development candidates for this toxin. Botulinum toxin is possibly the most acutely toxic substance known and a few molecules of this substance are sufficient to inhibit signal transfer between nerve and muscle cells leading to paralysis. Botulinum toxin plays a role in food poisoning and is probably best known for its use in cosmetic applications. More importantly, its potential as bio-weapon makes it the focus of intensive biomedical research world wide. 'The collaboration with the University of Massachusetts Dartmouth provides for NascaCell an exiting opportunity to exploit the potential of its key technologies, Microbodies™ and Aptamers, to not only support the research of our customer but to also use their outstanding expertise to develop Microbody™-based development candidates', stated Dr. Michael Blind, NascaCell`s Chief Scientific Officer. About NascaCell Technologies AG – www.nascacell.com NascaCell Technologies AG, based in Munich, is a global leading provider of a new generation of biomolecules. With the innovative Aptamer and MicrobodyTM technologies, the company supports customers in the target validation and drug discovery R&D areas. NascaCell also develops a line of products and drug development candidates based on the Microbody™ technology. About the University of Massachusetts Dartmouth – www.umassd.edu The University of Massachusetts Dartmouth is part of the five-campus University of Massachusetts system. Founded in 1895, the university is a public institution with a proud history of making high quality education accessible and providing research and service that strengthens the economy and culture of the region and the Commonwealth. Located in southeastern Massachusetts, the university comprises five colleges—the College of Arts & Sciences, the College of Engineering, the Charlton College of Business, the College of Nursing, and the College of Visual & Performing Arts—as well as the School for Marine Sciences and Technology. UMass Dartmouth offers more than 70 fields of study, with minors in more than 30 areas. There are nearly 9,000 students, which includes nearly 1,000 graduate students. Contact: NascaCell Technologies AG Dr. Michael Blind Chief Scientific Officer Phone: +49 (0)89-54 72 72-0 m.blind@nascacell.de InvestorPress GmbH Georg Breu Phone: +49(0)89 55 96 98 75 info@investorpress.de 18.10.2007 Financial News transmitted by DGAP ----------------------------------------------------------------------
Aktuelle News
Aktuelle Berichte
Keine Berichte gefunden
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden